The endocannabinoid system (ECS) has lately been proven to be an important, multifaceted
homeostatic regulator, which influences a wide-variety of physiological processes all over …

Triazole compounds containing three nitrogen atoms in the five-membered aromatic azole
ring are readily able to bind with a variety of enzymes and receptors in biological system via …

Though there is limited research confirming the purported topical benefits of cannabinoids, it
is certain that cutaneous biology is modulated by the human endocannabinoid system …

During the research and development of new drugs directed at the central nervous system,
there is a considerable attrition rate caused by their hampered access to the brain by the …

By using fragments endowed with interesting and complementary properties for the
treatment of Alzheimer's disease (AD), a new family of tacrine–4-oxo-4 H-chromene hybrids …

Tacrine and PBT2 (an 8-hydroxyquinoline derivative) are well-known drugs that inhibit
cholinesterases and decrease β-amyloid (Aβ) levels by complexation of redox-active metals …

To date, the pharmacotherapy of Alzheimer's disease (AD) has relied on
acetylcholinesterase (AChE) inhibitors (AChEIs) and, more recently, an N-methyl-D …

Two isomeric series of dual binding site acetylcholinesterase (AChE) inhibitors have been
designed, synthesized, and tested for their ability to inhibit AChE, butyrylcholinesterase …

BACKGROUND AND PURPOSE Cannabinoid CB1 receptor antagonists reduce food intake
and body weight, but clinical use in humans is limited by effects on the CNS. We have …

The endocannabinoid system (ECS) consists of two receptors (CB1 and CB2), several
endogenous ligands (primarily anandamide and 2-AG), and over a dozen ligand …